The Department of Health – Abu Dhabi (DoH), the emirate's healthcare regulator, has concluded its inaugural health and life sciences mission to China, according to statements released by the department. The delegation conducted 32 meetings and site visits across Beijing, Shanghai, and Shenzhen, engaging Chinese healthcare institutions, universities, and biotechnology firms.
Discussions focused on linking China's scientific, technological, and manufacturing capabilities with Abu Dhabi's clinical infrastructure, genomic data assets, and regulatory frameworks. Sector engagements covered artificial intelligence, precision medicine, advanced diagnostics, and next-generation therapies including cell therapies, biologics, drug discovery, and organoid-based research.
The delegation also examined potential cooperation in AI-native hospitals, surgical robotics, laboratory automation, advanced imaging, and brain-computer interfaces. Potential collaboration models explored include joint clinical evaluation, technology validation within Abu Dhabi's clinical environment, knowledge transfer, and manufacturing opportunities.
According to DoH, ties established during the visit are slated to progress at the Abu Dhabi Future Health Summit 2026, scheduled from 20 to 22 October, with 24 Chinese organisations invited to participate.
Sources
- Macau Business · 2026-10-17
